According to MarkNtel Advisors’ research report titled “Global Type-2 Diabetes Market Analysis, 2020”, the market is anticipated to grow at a CAGR of around 8% during 2020-25. Reports URL - https://www.marknteladvisors.com/research-library/global-type-2-diabetes-market.html

1. Global Type-2 Diabetes
Market Analysis, 2020
marknteladvisors.com

2. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 2
Document Outline
Table of Content
Market Segmentation, Scope of Work
05
Research Process & Methodology
Primary Research, Secondary Research, Companies Interviewed, Respondent Profile, Research
Methodology, Forecasting
21
Introduction
About Us, Key Questions Answered In This Study
02
Sample Pages
Global Type 2 Diabetes Market Analysis, 2020
29
Commercials 60
Disclaimer 62

3. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 3
Market Segmentation
• Dipeptidyl Peptidase-4 (DPP-4)
Inhibitors
• Alpha-glucosidase Inhibitors
• Biguanides
• Glucagon-Like Peptide-1 (GLP-
1) Receptor Agonists
• Sodium-Glucose Cotransporter
2 Inhibitors (SGLT2)
• Sulfonylureas
• Other (Thiazolidinediones,
meglitinides, glitazones, etc.)
Global Type 2 Diabetes Market Segmentation
• Male
• Female
By Drug Type By Gender
• North America
o The US
o Canada
o Mexico
• Europe
o The UK
o France
o Germany
o Spain
o Italy
o Others
• Asia-Pacific
o China
o Japan
o India
o South Korea
o Australia
o South East
Asia
o Others
• South America
o Brazil
o Argentina
o Others
• MEA
o UAE
o Saudi Arabia
o South Africa
o Others
By Region
• Merck & Co
• AstraZeneca
• Novo Nordisk
• Bristol-Myers
Squibb
• Eli Lilly
• Sanofi
• Boehringer
Ingelheim
• Pfizer
• Takeda
• Biocon
• Johnson &
Johnson
By Company
• Upto 19 years
• 20 – 65 years
• Above 65
years
By Age Group

4. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 4
Table of Content (1/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
1. Introduction
1.1. Research Process
1.2. Market Segmentation
1.3. Market Definition
1.4. Assumptions
2. Executive Summary
3. Expert Verbatim
4. Impact of Covid-19
4.1. Short Term Impact
4.2. Long Term Impact
5. Global Type 2 Diabetes Market Outlook, 2015-25F
5.1. Market Size & Analysis
5.1.1. Market Revenues
5.2. Market Share & Analysis
5.2.1. By Drug Type
5.2.1.1. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
5.2.1.2. Alpha-glucosidase Inhibitors
5.2.1.3. Biguanides
5.2.1.4. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
5.2.1.5. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2)

5. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 5
Table of Content (2/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
5.2.1.6. Sulfonylureas
5.2.1.7. Other (Thiazolidinediones, meglitinides, glitazones, etc.)
5.2.2. By Gender
5.2.2.1. Male
5.2.2.2. Female
5.2.3. By Age Group
5.2.3.1. Upto 19 years
5.2.3.2. 20 – 65 years
5.2.3.3. Above 65 years
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. South America
5.2.4.3. Europe
5.2.4.4. Middle East & Africa
5.2.4.5. Asia-Pacific
5.2.5. By Company
5.2.5.1. Revenue Shares
5.2.5.2. Strategic Factorial Indexing
5.2.5.3. Competitor Placement in MarkNtel Quadrant
5.3. Market Attractiveness Index

6. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 6
Table of Content (3/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
5.3.1. By Drug Type
5.3.2. By Gender
5.3.3. By Age Group
5.3.4. By Region
6. North America Type 2 Diabetes Market Outlook, 2015-25F
6.1. Market Size & Analysis
6.1.1. Market Revenues
6.2. Market Share & Analysis
6.2.1. By Drug Type
6.2.2. By Gender
6.2.3. By Age Group
6.2.4. By Country
6.2.4.1. The US
6.2.4.2. Canada
6.2.4.3. Mexico
6.3. Market Attractiveness Index
6.3.1. By Drug Type
6.3.2. By Gender
6.3.3. By Age Group
6.3.4. By Country

7. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 7
Table of Content (4/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
6.4. The US Type 2 Diabetes Market Outlook, 2015-25F
6.4.1.Market Size & Analysis
6.4.1.1. Market Revenues
6.4.2.Market Share & Analysis
6.4.2.1. By Drug Type
6.5. Canada Type 2 Diabetes Market Outlook, 2015-25F
6.5.1.Market Size & Analysis
6.5.1.1. Market Revenues
6.5.2.Market Share & Analysis
6.5.2.1. By Drug Type
6.6. Mexico Type 2 Diabetes Market Outlook, 2015-25F
6.6.1.Market Size & Analysis
6.6.1.1. Market Revenues
6.6.2.Market Share & Analysis
6.6.2.1. By Drug Type
6.7. Competitive Scenario for various Countries
6.7.1. Mapping Countries and Market Potential (High, Medium, Low)
6.7.2. Companies Dominating in Countries
7. South America Type 2 Diabetes Market Outlook, 2015-25F
7.1. Market Size & Analysis

8. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 8
Table of Content (5/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
7.1.1. Market Revenues
7.2. Market Share & Analysis
7.2.1. By Drug Type
7.2.2. By Gender
7.2.3. By Age Group
7.2.4. By Country
7.2.4.1. Brazil
7.2.4.2. Argentina
7.2.4.3. Others
7.3. Market Attractiveness Index
7.3.1. By Drug Type
7.3.2. By Gender
7.3.3. By Age Group
7.3.4. By Country
7.4. Brazil Type 2 Diabetes Market Outlook, 2015-25F
7.4.1.Market Size & Analysis
7.4.1.1. Market Revenues
7.4.2.Market Share & Analysis
7.4.2.1. By Drug Type
7.5. Argentina Type 2 Diabetes Market Outlook, 2015-25F

9. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 9
Table of Content (6/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
7.5.1.Market Size & Analysis
7.5.1.1. Market Revenues
7.5.2.Market Share & Analysis
7.5.2.1. By Drug Type
7.6. Competitive Scenario for various Countries
7.6.1. Mapping Countries and Market Potential (High, Medium, Low)
7.6.2. Companies Dominating in Countries
8. Europe Type 2 Diabetes Market Outlook, 2015-25F
8.1. Market Size & Analysis
8.1.1. Market Revenues
8.2. Market Share & Analysis
8.2.1. By Drug Type
8.2.2. By Gender
8.2.3. By Age Group
8.2.4. By Country
8.2.4.1. The UK
8.2.4.2. Germany
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain

10. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 10
Table of Content (7/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
8.2.4.6. Others
8.3. Market Attractiveness Index
8.3.1. By Drug Type
8.3.2. By Gender
8.3.3. By Age Group
8.3.4. By Country
8.4. The UK Type 2 Diabetes Market Outlook, 2015-25F
8.4.1.Market Size & Analysis
8.4.1.1. Market Revenues
8.4.2.Market Share & Analysis
8.4.2.1. By Drug Type
8.5. Germany Type 2 Diabetes Market Outlook, 2015-25F
8.5.1.Market Size & Analysis
8.5.1.1. Market Revenues
8.5.2.Market Share & Analysis
8.5.2.1. By Drug Type
8.6. France Type 2 Diabetes Market Outlook, 2015-25F
8.6.1.Market Size & Analysis
8.6.1.1. Market Revenues
8.6.2.Market Share & Analysis

11. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 11
Table of Content (8/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
8.6.2.1. By Drug Type
8.7. Italy Type 2 Diabetes Market Outlook, 2015-25F
8.7.1.Market Size & Analysis
8.7.1.1. Market Revenues
8.7.2.Market Share & Analysis
8.7.2.1. By Drug Type
8.8. Spain Type 2 Diabetes Market Outlook, 2015-25F
8.8.1.Market Size & Analysis
8.8.1.1. Market Revenues
8.8.2.Market Share & Analysis
8.8.2.1. By Drug Type
8.9. Competitive Scenario for various Countries
8.9.1. Mapping Countries and Market Potential (High, Medium, Low)
8.9.2. Companies Dominating in Countries
9. Middle East & Africa Type 2 Diabetes Market Outlook, 2015-25F
9.1. Market Size & Analysis
9.1.1. Market Revenues
9.2. Market Share & Analysis
9.2.1. By Drug Type
9.2.2. By Gender

12. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 12
Table of Content (9/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
9.2.3. By Age Group
9.2.4. By Country
9.2.4.1. UAE
9.2.4.2. Saudi Arabia
9.2.4.3. South Africa
9.2.4.4. Others
9.3. Market Attractiveness Index
9.3.1. By Drug Type
9.3.2. By Gender
9.3.3. By Age Group
9.3.4. By Country
9.4. UAE Type 2 Diabetes Market Outlook, 2015-25F
9.4.1.Market Size & Analysis
9.4.1.1. Market Revenues
9.4.2.Market Share & Analysis
9.4.2.1. By Drug Type
9.5. Saudi Arabia Type 2 Diabetes Market Outlook, 2015-25F
9.5.1.Market Size & Analysis
9.5.1.1. Market Revenues
9.5.2.Market Share & Analysis

13. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 13
Table of Content (10/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
9.5.2.1. By Drug Type
9.6. South Africa Type 2 Diabetes Market Outlook, 2015-25F
9.6.1.Market Size & Analysis
9.6.1.1. Market Revenues
9.6.2.Market Share & Analysis
9.6.2.1. By Drug Type
9.7. Competitive Scenario for various Countries
9.7.1. Mapping Countries and Market Potential (High, Medium, Low)
9.7.2. Companies Dominating in Countries
10. Asia-Pacific Type 2 Diabetes Market Outlook, 2015-25F
10.1. Market Size & Analysis
10.1.1. Market Revenues
10.2. Market Share & Analysis
10.2.1. By Drug Type
10.2.2. By Gender
10.2.3. By Age Group
10.2.4. By Country
10.2.4.1. China
10.2.4.2. India
10.2.4.3. Japan

14. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 14
Table of Content (11/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
10.2.4.4. South Korea
10.2.4.5. Australia
10.2.4.6. South East Asia
10.2.4.7. Others
10.3. Market Attractiveness Index
10.3.1. By Drug Type
10.3.2. By Gender
10.3.3. By Age Group
10.3.4. By Country
10.4. China Type 2 Diabetes Market Outlook, 2015-25F
10.4.1. Market Size & Analysis
10.4.1.1. Market Revenues
10.4.2. Market Share & Analysis
10.4.2.1. By Drug Type
10.5. India Type 2 Diabetes Market Outlook, 2015-25F
10.5.1. Market Size & Analysis
10.5.1.1. Market Revenues
10.5.2. Market Share & Analysis
10.5.2.1. By Drug Type
10.6. Japan Type 2 Diabetes Market Outlook, 2015-25F

15. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 15
Table of Content (12/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
10.6.1. Market Size & Analysis
10.6.1.1. Market Revenues
10.6.2. Market Share & Analysis
10.6.2.1. By Drug Type
10.7. South Korea Type 2 Diabetes Market Outlook, 2015-25F
10.7.1. Market Size & Analysis
10.7.1.1. Market Revenues
10.7.2. Market Share & Analysis
10.7.2.1. By Drug Type
10.8. Australia Type 2 Diabetes Market Outlook, 2015-25F
10.8.1. Market Size & Analysis
10.8.1.1. Market Revenues
10.8.2. Market Share & Analysis
10.8.2.1. By Drug Type
10.9. South East Asia Type 2 Diabetes Market Outlook, 2015-25F
10.9.1. Market Size & Analysis
10.9.1.1. Market Revenues
10.9.2. Market Share & Analysis
10.9.2.1. By Drug Type
10.10. Competitive Scenario for various Countries

16. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 16
Table of Content (13/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
10.10.1. Mapping Countries and Market Potential (High, Medium, Low)
10.10.2. Companies Dominating in Countries
11. Global Type 2 Diabetes Regulations, Product Standards
12. Global Type 2 Diabetes Value Chain Analysis
13. Consumer Behavior Analysis
13.1. Consumer Trends and Preferences
13.2. Factors Affecting Buying Decision
14. Global Type 2 Diabetes Market Dynamics
14.1. Drivers
14.2. Challenges
14.3. Impact Analysis
15. Global Type 2 Diabetes Market Hotspots & Opportunities
16. Global Type 2 Diabetes Market Trends & Insights
17. Global Type 2 Diabetes Price Analysis
18. Global Type 2 Diabetes Market Key Strategic Imperatives for Success & Growth
19. Competition Outlook
19.1. Competitor Wise Growth Strategies
19.1.1. Product Portfolio
19.1.2. Target Market
19.1.3. Target Age Group

17. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 17
Table of Content (14/14)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
19.1.4. Manufacturing Units
19.1.5. Research & Development
19.1.6. Strategic Alliances & Initiatives
19.2. Company Profiles of top companies (Business Description, Product Segments, Business Segments, Financials,
Strategic Alliances/ Partnerships, Future Plans)
19.2.1. Merck & Co
19.2.2. AstraZeneca
19.2.3. Novo Nordisk
19.2.4. Bristol-Myers Squibb
19.2.5. Eli Lilly
19.2.6. Sanofi
19.2.7. Boehringer Ingelheim
19.2.8. Pfizer
19.2.9. Takeda
19.2.10. Biocon
19.2.11. Johnson & Johnson
20. Disclaimer

18. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 18
Document Outline
Table of Content
Market Segmentation, Scope Of Work
05
Research Process & Methodology
Primary Research, Secondary Research, Companies Interviewed, Respondent Profile, Research
Methodology, Forecasting
21
Introduction
About Us, Key Questions Answered In This Study
02
Sample Pages
Global Type 2 Diabetes Market Analysis, 2020
29
Commercials 60
Disclaimer 62

19. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved.
Global Type 2 Diabetes Market Outlook, 2015-2025F

20. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 20
Global Type 2 Diabetes Market Outlook, By Revenues
Figure XX: Global Type 2 Diabetes Market Revenues (USD Million), 2015- 2025F
• The surging number of patients diagnosed from type 2 diabetes is driving the global market since 2015. The Western Pacific, North
America, and the Caribbean are the topmost regions that have a large number of individuals with type 2 diabetes. According to
International, Diabetes Federation (IDF), 1 in 6 inhabitants aged 20-79 years at risk of developing type 2 diabetes in North America and
the Caribbean region. Changing lifestyle and rising overweight population would add more type 2 diabetes patients, which would generate
the additional requirement for multiple drug therapies across the globe.
• The outbreak of COVID-19 is anticipated to impact the global type 2 diabetes market in 2020. GLP-1 Receptor Agonists and DPP-4
Inhibitors are helping diabetes patients to manage immune overreaction caused by a coronavirus. The burgeoning incidence of
coronavirus in type 2 diabetes patients is anticipated to propel the type 2 diabetes market in the next few years.
2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F
CAGR
CAGR
Revenue: XX% Revenue: XX%
Source: MarkNtel Advisors

21. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 21
Global Type 2 Diabetes Market Outlook, By Revenues
Regions 2019 (Million)
Europe 37
Western Pacific 137
South-East Asia 31
Middle East & North Africa 35
Africa 45
South & Central America 34
North America & Caribbean 55
Number of individuals aged 20–79 years with Type 2 diabetes worldwide
Source: International Diabetes Federation

22. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 22
Global Type 2 Diabetes Market Revenue Share, By Drug Type
Figure XX: Global Type 2 Diabetes Market Revenue Share (%), By Drug Type, 2019 & 2025F
• The non-insulin therapeutics comprise Standard of Care (SOC)
therapy and add-on to SOC are the first-line therapy that is
used for the treatment of type 2 diabetic patients. Standard of
Care therapy drugs include biguanides, alpha-glucosidase
inhibitors, and sulfonylureas. Biguanides is majorly used drug
across the globe particularly in the United States and European
countries. The intensifying number of type 2 diabetes
treatment globally in the coming years is anticipated to
generate demand for Standard of Care therapy drugs.
Therefore, expected that biguanides, alpha-glucosidase
inhibitors, and sulfonylureas segments would surge during the
forecasting years 2020-25.
• Dipeptidyl peptidase-4 (DPP-4) inhibitors drugs are prescribed
to patients owing to their safety and tolerability in addition to
SOC in case SOC therapy drugs are inadequate to manage high
blood glucose on their own. In Asia-Pacific countries,
particularly in Japan, dipeptidyl peptidase-4 (DPP-4) inhibitors
prescribed majorly at first-line therapy. Thereby, the dipeptidyl
peptidase-4 (DPP-4) inhibitors segment is supposed to
augment over the next 5 years.
2019 2025F
 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
 Alpha-glucosidase Inhibitors
 Biguanides
 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
 Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2)
 Sulfonylureas
 Others
Source: MarkNtel Advisors
*These are dummy charts and do not represent actual value

23. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 23
Global Type 2 Diabetes Market Revenue Share, By Gender
Figure XX: Global Type 2 Diabetes Market Revenue Share (%), By Gender, 2019 - 2025F
• The number of female patients suffering from type 2 diabetes have registeredan exponential growth over the past couple of years.
Furthermore, pregnant women diagnosed with gestational diabetes are at high prevalence of rising type 2 disease in the future as well as
their children. Europe, South East Asia, and North America and the Caribbean are the regions that have a risk of developing gestational
diabetes above 15% as per the International Diabetes Federation. Therefore, it is projected that the female segment would grow by 2025.
• While the rising number of cases related to Impaired Fasting Glycemia (IFG) and Impaired Glucose Tolerance (IGT) amid the male
population due to increasing obesity, high cholesterol, high blood pressure, etc. are augmenting the possibility of progressing type 2
diabetes.
2019 2020 2021 2022 2023 2024 2025
Male Female
*These are dummy charts and do not represent actual value Source: MarkNtel Advisors

24. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 24
Global Type 2 Diabetes Market Revenue Share & Market Size, By Age Group
Figure XX: Global Type 2 Diabetes Market Revenue Share (%), By Age Group, 2019 & 2025F
• Above 65 years: The beta cells proliferative ability decreases with age,
which leads to rapid apoptosis. The declining beta-cell proliferation is
associated with the decreased expression of cell cycle activators and
augmented expression of cell cycle inhibitors, causing type 2 diabetes.
Above 65 years of age, more than 50% of inhabitants diagnosed with
Type 2 diabetes in developed countries. According to the United
Nation, the population aged 65 or more were 703 million in 2019 and
would reach to 1.5 billion by 2050. The increasing geriatric
population is expected to surge the incidences of type 2 diabetes over
the next 5 years. Therefore, anticipated that demand for drugs is
augmenting in the coming years for treating type 2 diabetes in the
elderly population. Hence, the above 65 years segment is supposed to
rise by 2025.
 Upto 19 years  20 – 65 years  Above 65 years
2015 2019 2025
Upto 19 years
20 – 65 years
Above 65 years
Figure XX: Global Type 2 Diabetes Market Size (USD Million), By Age Group, 2015, 2019 & 2025F
Source: MarkNtel Advisors
*These are dummy charts and do not represent actual value
2019 2025F
*These are dummy charts and do not represent actual value

25. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 25
Global Type 2 Diabetes Market Revenue Share, By Region
Figure XX: Global Type 2 Diabetes Market Revenue Share (%), By Region, 2019 & 2025F
Source: MarkNtel Advisors
2019: X%
2025F: X%
2019: X%
2025F: X%
2019: X%
2025F: X%
2019: X%
2025F: X%
2019: X%
2025F: X%
2019: X%
2025F: X%

26. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved.
Asia-Pacific Type 2 Diabetes Market Outlook, 2015-2025F

27. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 27
Asia-Pacific Type 2 Diabetes Market Outlook, By Revenues
Figure XX: Asia-Pacific Type 2 Diabetes Market Revenues (USD Million), 2015- 2025F
• Asia-Pacific expected to grow at the highest CAGR during 2020-25 that contributes to the positive growth of the global market. Some
reasons that are aiding the Asia-Pacific market growth are as follows:
• The number of type 2 diabetes incidence is surging in the Western Pacific and Southeast Asia regions. 1 in 3 of inhabitants aged 20-
79 years at risk of developing type 2 diabetes in the Western-Pacific region as per the International Diabetes Federation.
• The type 2 diabetes caused various diseases such as cardiovascular, kidney damage, stroke, etc. the rising awareness regarding the
adverse effect of diabetes is pushing patients for treatment worldwide.
• The advancement in medications by manufacturing companies is also rising the Asia-Pacific market. sodium-glucose cotransporter
2 inhibitor is among the advanced medication introduced in the market.
2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F
CAGR
CAGR
Revenue: XX% Revenue: XX%
Source: MarkNtel Advisors

28. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 28
Asia-Pacific Type 2 Diabetes Market Revenue Share, By Drug Type
Figure XX: Asia-Pacific Type 2 Diabetes Market Revenue Share (%), By Drug Type, 2015 - 2025F
Regions 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dipeptidyl Peptidase-4
(DPP-4) Inhibitors
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Alpha-glucosidase
Inhibitors
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Biguanides XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Glucagon-Like Peptide-1
(GLP-1) Receptor
Agonists
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Sodium-Glucose
Cotransporter 2
Inhibitors (SGLT2)
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Sulfonylureas XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Others XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Source: MarkNtel Advisors

29. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 29
Asia-Pacific Type 2 Diabetes Market Revenue Share & Market Size, By Gender
Figure XX: Asia-Pacific Type 2 Diabetes Market Revenue Share (%), By Gender, 2019 & 2025F
2019 2020 2021 2022 2023 2024 2025
Male
Female
Figure XX: Asia-Pacific Type 2 Diabetes Market Size (USD Million), By Gender, 2019 - 2025F
 Male
 Female
2019 2025F
Source: MarkNtel Advisors
*These are dummy charts and do not represent actual value
*These are dummy charts and do not represent actual value Source: MarkNtel Advisors

30. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 30
Asia-Pacific Type 2 Diabetes Market Revenue Share & Market Size, By Age Group
Figure XX: Asia-Pacific Type 2 Diabetes Market Revenue Share (%), By Age Group, 2019 & 2025F
 Upto 19 years
 20 – 65 years
 Above 65 years
2015 2019 2025
Upto 19 years
20 – 65 years
Above 65 years
Figure XX: Asia-Pacific Type 2 Diabetes Market Size (USD Million), By Age Group, 2015, 2019 & 2025F
2019
XX%
XX%
XX%
2025F
XX%
XX%
XX%
Source: MarkNtel Advisors
*These are dummy charts and do not represent actual value
*These are dummy charts and do not represent actual value Source: MarkNtel Advisors

31. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved.
China Type 2 Diabetes Market Outlook, 2015-2025F

32. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 32
China Type 2 Diabetes Market Outlook, By Revenues
Figure XX: China Type 2 Diabetes Market Revenues (USD Million), 2015- 2025F
• China type 2 diabetes market is projected to boost in the forthcoming years. Some factors that contribute to the positive growth of the
market are as follows:
o The rising number of drug-treated patients and around 10.9% prevalence of generating type 2 diabetes in the country is
intensifying the use of Glucagon-like Peptide 1 (GLP-1) receptor agonists and Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the
coming years. Hence, projected that the China market would propel by 2025.
o The increasing promotion activities of type 2 diabetes drug is surging awareness about the different medication among end-users,
that support the market to grow by 2025. For instance: Mitsubishi Tanabe Group and Servier China signed an agreement in 2019
to promote the type 2 diabetes drug Tenelia (Teneligliptin Hydrobromide Hydreate).
2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F
CAGR
CAGR
Revenue: XX% Revenue: XX%
Source: MarkNtel Advisors

33. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 33
China Type 2 Diabetes Market Revenue Share, By Drug Type
Figure XX: China Type 2 Diabetes Market Revenue Share (%), By Drug Type, 2015 - 2025F
Regions 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dipeptidyl Peptidase-4
(DPP-4) Inhibitors
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Alpha-glucosidase
Inhibitors
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Biguanides XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Glucagon-Like Peptide-1
(GLP-1) Receptor
Agonists
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Sodium-Glucose
Cotransporter 2
Inhibitors (SGLT2)
XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Sulfonylureas XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Others XX% XX% XX% XX% XX% XX% XX% XX% XX% XX% XX%
Source: MarkNtel Advisors

34. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 34
+1 (613) 707-5086
sales@marknteladvisors.com